Crizotinib in Chinese Patients with ROS1 -Rearranged Advanced Non ‒Small-Cell Lung Cancer in Routine Clinical Practice
ConclusionCrizotinib was effective and well tolerated in Chinese patients withROS1-positive advanced NSCLC in real-world clinical practice. The progression sites and patterns, as well as treatments after first disease progression on crizotinib were diverse. Crizotinib beyond progressive disease and local therapy after failure of crizotinib treatment were feasible and effective in clinical practice.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | China Health | Cytology | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Oral Cancer | Smokers